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Volatile anaesthetics exert protective effects on the heart against perioperative ischaemic injury. However, there is
growing evidence that these cardioprotective properties are reduced in case of type 2 diabetes mellitus. A strong
predictor of postoperative cardiac function is myocardial substrate metabolism. In the type 2 diabetic heart,
substrate metabolism is shifted from glucose utilisation to fatty acid oxidation, resulting in metabolic inflexibility
and cardiac dysfunction. The ischaemic heart also loses its metabolic flexibility and can switch to glucose or fatty
acid oxidation as its preferential state, which may deteriorate cardiac function even further in case of type 2
diabetes mellitus.
Recent experimental studies suggest that the cardioprotective properties of volatile anaesthetics partly rely on
changing myocardial substrate metabolism. Interventions that target at restoration of metabolic derangements, like
lifestyle and pharmacological interventions, may therefore be an interesting candidate to reduce perioperative
complications. This review will focus on the current knowledge regarding myocardial substrate metabolism during
volatile anaesthesia in the obese and type 2 diabetic heart during perioperative ischaemia.
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Perioperative cardiac complications occur in 2-5% of all
non-cardiac surgical procedures, which globally affect
5–12 million patients each year [1]. More specifically,
0.65% of these patients develop perioperative myocardial
infarction or cardiac arrest [2]. Perioperative cardiac com-
plications are an economical, medical and social burden
that warrants optimisation of perioperative health and car-
diovascular care to improve patient outcome and reduce
health care costs. There are several well-known predictors
for perioperative cardiac complications identified, such as
type of surgery, ASA classification and increasing age [1,2].
Additionally, lifestyle risk factors associated with metabolic
alterations, such as excessive dietary intake and physical
inactivity, are strongly associated with clinical risk factors
that predict perioperative cardiovascular complications [1].* Correspondence: c.vandenbrom@vumc.nl
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distribution, and reproduction in any mediumLifestyle risk factors related to obesity and type 2
diabetes mellitus (T2DM) have become an epidemic
over the last decade. Worldwide, 366 million people
have T2DM [3]. It is predicted that in the year 2030
about 552 million people will have overt diabetes, mainly
T2DM [3]. Patients with T2DM are more likely to develop
coronary artery disease and myocardial ischaemia [4] and
have an increased cardiovascular complication rate after
major non-cardiac surgery [5].
In addition to prevention programs to reduce the
burden of metabolic disease on the perioperative process,
there are intraoperative cardioprotective strategies available
that may reduce the impact of ischaemic injury during and
after surgery, like the application of the volatile anaesthetics
sevoflurane and isoflurane. These volatile anaesthetics exert
multiple protective effects that enhance perioperative
preservation of the heart in patients [6] and rats [7].
Although exposure to volatile anaesthetics reduced
infarct size and improved post-ischaemic recovery in
healthy rats [7], the cardioprotective effects of these
agents are reduced in obese [8] and hyperglycaemic [9]Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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are one of the hypothetical mechanisms that may explain
the suppressed cardioprotective capacity in T2DM [10-12].
It is however not yet understood how these myocardial
metabolic alterations affect intraoperative cardioprotective
mechanisms.
In order to elucidate the impact of altered myocardial
substrate metabolism on intraoperative myocardial
protection, this review will focus on available preclinical
knowledge regarding myocardial substrate metabolism
during volatile anaesthesia in the obese/T2DM heart
under normal conditions and in the context of ischaemia.
We first describe myocardial substrate metabolism under
healthy, obese/T2DM and ischaemic conditions, followed
by an overview of the interaction between substrate
metabolism and volatile anaesthetics in the context of
perioperative ischaemia and reperfusion injury. Finally,
we propose strategies to modulate myocardial substrate
metabolism that may contribute to an improvement of
myocardial protective capacity and perioperative and
postoperative outcome in obesity and T2DM.
Myocardial substrate metabolism
Fatty acids and carbohydrates are essential for the pump
function of the heart [13]. Under physiological condi-
tions, myocardial contractile function relies on oxidation
of fatty acids (60-70%), glucose (30-40%) and to a lesser
extent lactate, ketones, amino acids and pyruvate (10%)
to generate adenosine triphosphate (ATP) [14-16]. The
heart exerts a metabolic flexibility, and myocardial sub-
strate utilisation depends on substrate availability, nutri-
tional status, and exercise level. With glucose as the
more energetically efficient substrate, the healthy heart
is able to switch to glucose under conditions of stress,
such as ischaemia, pressure overload or in heart failure.
Glucose metabolism is regulated through multiple
steps, including uptake, glycolysis and pyruvate decarb-
oxylation. Myocardial glucose supply is regulated 1) via
circulating glucose levels or 2) by release of glucose from
intracellular glycogen stores [17]. Myocardial glucose
uptake depends on the sarcolemmal glucose transporter
GLUT1 (insulin-independent) and the dominant glucose
transporter GLUT4 (insulin-dependent) (Figure 1) [18].
After uptake, glucose is broken down into pyruvate by gly-
colysis, consumed by the mitochondria and decarboxylated
into acetyl-CoA by pyruvate dehydrogenase. Acetyl-
CoA enters the tricarboxylic acid cycle with entry of
reducing equivalents to the electron transport chain and
oxidative phosphorylation, which finally leads to ATP
formation (Figure 1).
Fatty acid metabolism consists of uptake, oxidation
and esterification. There are two sources of fatty acids for
myocardial metabolism: 1) circulating albumin bound fatty
acids derived from adipose tissue via lipolysis or 2) releasedfrom triglyceride-rich lipoproteins from the liver [19]. Fatty
acids enter cardiomyocytes by simple diffusion and via
transport through three different membrane fatty acid
transporters – fatty acid translocase (FAT)/CD36, fatty acid
transport protein (FATP1/6) and plasma membrane fatty
acid binding protein (FABPpm) (Figure 1) [19]. After
sarcolemmal uptake, intracellular fatty acids are activated
to form fatty acyl-CoA, which can undergo beta-oxidation
or esterification to form intracellular triglycerides [20].
Fatty acid oxidation requires fatty acyl-CoA entry into
the mitochondria, which is dependent on the activity of
carnitine palmitoyl transferase (CPT-1) [21]. After
translocation into the mitochondria, fatty acyl-CoA can
enter the beta-oxidation pathway to form acetyl-CoA and
subsequently ATP (Figure 1). Under physiological con-
ditions, 70-90% of the fatty acids that enter cardiomyocytes
are oxidised for ATP generation, whereas 10-30% is
converted to triglycerides by lipoprotein lipase [22]. In
case of energy expenditure, intracellular triglyceride
stores can be hydrolysed as an endogenous fatty acid
source, which is explanatory for 10% of the total fatty
acid utilisation in the heart [23].
Type 2 diabetes mellitus
Alterations in myocardial substrate metabolism in T2DM
hearts are extensively reviewed by others [15,22,24]. In
short, myocardial fatty acid metabolism is initially enhanced
in T2DM hearts, with increased rates of fatty acid oxidation
and esterification [25,26]. There are two proposed mecha-
nisms that may underlie this derangement: 1) increased
fatty acid uptake due to increased substrate supply and
augmented expression and localisation of sarcolemmal fatty
acid transporters [26] and 2) increased oxidation and esteri-
fication due to changes in regulation at both the enzymatic
and transcriptional level [26].
In addition, a decreased myocardial glucose metabolism
is a concomitant feature of the T2DM heart [25,26]. The
slow rate of glucose transport across the sarcolemmal
membrane due to decreased glucose transporters leads to
a restriction of glucose oxidation. Accordingly, fatty
acid oxidation has an inhibitory effect on the pyruvate
dehydrogenase complex due to increased fatty acid
supply. Taken together, the T2DM heart has a distinct
metabolic phenotype, characterised by enhanced myocar-
dial fatty acid metabolism and a concomitant reduction in
myocardial glucose metabolism.
Ischaemia
Myocardial ischaemia occurs when coronary perfusion is
inadequate to maintain a sufficient oxygen supply/demand
ratio. Ischaemia influences both myocardial substrate me-
tabolism and myocardial function. The pathophysiological























Figure 1 Glucose and fatty acid metabolism in the cardiomyocyte. Glucose uptake into the cell occurs through the glucose transporters
GLUT1 and GLUT4. Once inside, glucose is broken down into pyruvate by glycolysis. Pyruvate is subsequently transported into the mitochondria
and decarboxylated to acetyl-CoA. Non-esterified fatty acids are taken up through fatty acid transporter (FAT)/CD36, fatty acid transport protein
(FATP) and plasma membrane fatty acid binding protein (FABPpm). Intracellular fatty acids form fatty acyl-CoA and can either be esterified into
triglycerides (TG) or enter the mitochondria via carnitine palmitoyl transferase (CPT-1). Fatty acyl-CoA enters the β-oxidation pathway, forming
acetyl-CoA. Glucose or fatty acid-derived acetyl-CoA enters the tricarboxylic acid (TCA) cycle with entry of reducing equivalents to the electron
transport chain and oxidative phosphorylation, and finally ATP is formed.
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depleted, ionic homeostasis is disturbed and contractile
dysfunction is caused. The energetic demand of the
heart changes in case of myocardial ischaemia. The heart
usually responds to injury by increasing myocardial
glucose metabolism to improve its energetic efficiency
[22,24]. However, increased adipose tissue lipolysis
results in increased plasma free fatty acid concentrations,
which may increase myocardial fatty acid utilisation and
esterification [27]. In this context, glycolysis becomes an
important source of energy due to its ATP-generating
ability in the absence of oxygen. It is also suggested that in
the early phase of ischaemia, fatty acid oxidation shifts to
the more efficient glucose oxidation, followed by a decrease
in total substrate oxidation [24]. Increased glycolysis can
parallel depression of myocardial glucose and fatty
acid oxidation depending on the severity of ischaemia.
Overall, the ischaemic heart favours the energetically more
efficient glucose (3.17 ATP/oxygen molecule) over fatty
acid oxidation (2.83 ATP/oxygen molecule) [28]. This
flexibility additionally depends on substrate availability,
oxygen supply, tissue vascularisation and myocardial
workload. In conclusion, the metabolic state of the
ischaemic heart is characterised by imbalances in sub-
strate availability and utilisation and is also influenced
the severity of ischaemia.The combination of type 2 diabetes mellitus and ischaemia
The cardiometabolic profile of patients with T2DM
makes them more prone to develop plaque formation
and intravascular stenosis, leading to the development of
stroke or myocardial infarction. In addition, these
patients are more susceptible to subsequent episodes of
ischaemia [29,30]. Whereas the metabolic undisturbed
heart usually responds to injury by increasing myocardial
glucose metabolism [22,24], this adaptive response is
inhibited by insulin resistance, which is a characteristic of
obesity and T2DM. This inhibition results in increased
myocardial fatty acid metabolism [31,32], increased
oxygen consumption, decreased cardiac efficiency [31]
and altered myocardial perfusion [33]. In obese or T2DM
animals subjected to myocardial ischaemia the findings
are inconclusive. It has been shown that obesity reduced
ischaemia and reperfusion injury [34] and myocardial
function during ischaemia (and reperfusion) [35-40], but
also similar ischaemia and reperfusion injury was found
[41]. Additionally, increased glucose oxidation and de-
creased fatty acid oxidation after myocardial infarction
was found, which was ameliorated in obese rats [40].
Obese rats with insulin resistance resulted in preserved
myocardial function [36] or aggravated [36,42-44] ischae-
mia and reperfusion injury. Moreover, the combination of
insulin resistance, dyslipidaemia and hypertension in obese
van den Brom et al. Cardiovascular Diabetology 2013, 12:42 Page 4 of 13
http://www.cardiab.com/content/12/1/42animals seems to increase the susceptibility of the heart to
ischaemia (and reperfusion) injury [45-48]. Others however
reported that myocardial injury during ischaemia was
unaffected in T2DM rats, independent of the severity of
T2DM [49]. In case of genetically induced T2DM rats in
combination with a high cholesterol diet, ischaemic injury
was however exacerbated [50]. As stated earlier, these
inconclusive results in animal experiments suggest that the
type and severity of T2DM may influence the sensitivity of
the heart to ischaemic insults.
With regard to myocardial substrate metabolism,
endogenous glycogen stores may support increased glucose
availability as substrate for the heart, and may thus be
beneficial in case of ischaemic injury. However, whether
pre-ischaemic glycogen levels are beneficial or detrimental
depends on the duration of T2DM [51] and to the extent
of glycogen depletion during ischaemia [52].
Overall, the effects of imbalanced myocardial substrate
metabolism during ischaemia in T2DM are inconclusive.
These observed contrasts may be due to differences in
the severity of ischaemia, the measured outcome parameter,
exogenous circumstances and the severity of the experi-
mental model for T2DM [32,53].
Effects of volatile anaesthetics in animals
Cardioprotective effects during ischaemia
Sevoflurane and isoflurane are commonly used volatile
anaesthetics. Sevoflurane and isoflurane make the rat
heart more resistant to ischaemia and reperfusion injury
[54-58]. It has been shown that proteins related to
myocardial substrate metabolism are, amongst others,
affected by sevoflurane-induced cardioprotection. PI3K
and Akt, which regulate translocation of glucose
transporter 4 (GLUT4) to the sarcolemma for glucose
uptake, are increased during sevoflurane in the isolated
ischaemic rat heart [59]. Moreover, sevoflurane enhances
GLUT4 expression in lipid rafts, increases glucose oxida-
tion and decreases fatty acid oxidation after ischaemia and
reperfusion injury in isolated working rat hearts compared
to untreated ischaemic hearts [10]. In the same study, no
alterations in AMP activated protein kinase (AMPK)
phosphorylation, pyruvate dehydrogenase activity and
glycogen content were found, whereas sevoflurane
decreased triglycerides and ceramide levels after ischaemia
and reperfusion injury [10].
Moreover, volatile anaesthetics are also known to alter
mitochondrial function, which is nicely reviewed by
Stadnicka et al. [60]. In short, it has been shown that
sevoflurane and isoflurane open mitochondrial ATP-
activated potassium (mito KATP) channels [61,62], activates
reactive oxygen species [62] and thereby alters mitochon-
drial metabolism [63].
Together, these results suggest a role for myocardial
substrate metabolism in the cardioprotective effects ofvolatile anaesthesia during ischaemia and reperfusion
injury in animals, although evidence is limited.
Myocardial substrate metabolism during volatile
anaesthesia
In rats, it has been shown that in vivo myocardial
glucose uptake was increased in the heart during isoflurane
(2 vol%) when compared to sevoflurane (3.5 vol%) [64]. An
explanation could be the differences by more stable blood
glucose levels during sevoflurane. However, a limitation of
this study was that the effects were not compared with
findings in awake rats or using non-volatile anaesthetics.
Others found that isoflurane (2 vol%) increased myocardial
glucose uptake compared to awake mice [65].
The effects of sevoflurane on myocardial substrate
metabolism have only been studied ex vivo. Sevoflurane
(2 vol%) decreased FAT/CD36 in lipid rafts and fatty
acid oxidation in isolated rat hearts [12]. And, although
studied in skeletal muscle cells, sevoflurane (2.6-5.2%)
increased glucose uptake [66]. Altogether, these results
suggest that isoflurane and sevoflurane might switch
myocardial metabolism to glucose as energetically more
efficient substrate.
Volatile anaesthesia is also known to affect pancreatic
insulin release. In isolated rat pancreatic islets, enflurane
[67] and isoflurane [68] have an inhibitory effect on
glucose-stimulated insulin release. In rats, isoflurane
impaired glucose-induced insulin release [69], whereas
sevoflurane impaired glucose tolerance [70], which both
resulted in hyperglycaemia. Therefore it seems that
impaired insulin release during volatile anaesthesia
might have a negative effect on substrate metabolism.
However, the beneficial cardioprotective effects may out-
weigh the adverse effects of impaired insulin secretion,
as the American Heart Association 2007 guidelines on
‘perioperative cardiovascular evaluation and care for non
cardiac surgery’ suggested that it can be beneficial to use
volatile anaesthetics during non cardiac surgery for
maintenance of general anaesthesia in haemodynamically
stable patients at risk for myocardial ischaemia [1].
Alterations in cardioprotective mechanisms in the
metabolic altered heart
The healthy heart is capable of protecting itself against
stressors like ischaemia by the flexibility to switch
between circulating substrates. These cardioprotective
properties might be enlarged during volatile anaesthesia.
On the other hand, the obese/T2DM heart is less
capable of switching between circulating substrates,
which may contribute to a reduced intrinsic protective
capacity. It is generally acknowledged that the incidence of
perioperative cardiovascular complications is increased in
patients with T2DM after non-cardiac surgery [5]. Accord-
ingly, blood glucose concentrations at admission correlated
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myocardial infarction [71], suggesting that T2DM may
affect perioperative cardiovascular risk. The next para-
graphs focus on available experimental knowledge
whether obesity, insulin resistance, hyperlipidaemia and
hyperglycaemia, important hallmarks of T2DM, exert
a cumulative effect on endogenous and exogenous
cardioprotective mechanisms.
Obesity and insulin resistance
It has been shown that obesity and insulin resistance
inhibit the cardioprotective effects of ischaemic pre- [72]
and postconditioning [73]. In high fat diet-induced
obese rats, sevoflurane preconditioning failed to induce
cardioprotection during myocardial ischemia and reperfu-
sion injury [41]. Moreover, sevoflurane postconditioning
did not protect the heart against myocardial and reperfu-
sion injury in obese and insulin resistant Zucker rats [8],
however, more research is necessary to draw a conclusion.
Hyperlipidaemia
The hyperlipidaemic heart has difficulties to adapt to
stressors like ischaemia, suggesting that cardioprotective
mechanisms are impaired. In rats it has been shown
that pacing-induced cardioprotection [74] and ischaemic-
induced preconditioning [75] was inhibited by hyper-
cholesterolaemia. Sevoflurane preconditioning reduced
myocardial infarct size in normocholesterolaemic rats,
which was blocked in hypercholesterolaemic rats [76].
Further research is warranted to study the impact of
hyperlipidaemia on anaesthesia-induced cardioprotection.
Acute hyperglycaemia
Hyperglycaemia is an independent predictor of cardio-
vascular risk [71]. The glycometabolic state upon
hospital admission is associated with the mortality risk in
T2DM patients with acute myocardial infarction [77]. It
has further been shown that hyperglycaemia inhibits
the cardioprotective capacity during desflurane-induced
preconditioning [78], isoflurane-induced preconditioning
[9,79] and sevoflurane-induced postconditioning in the
experimental setting [80]. Accordingly, infarct size was
directly related to the severity of hyperglycaemia [81,82],
whereas the inhibited cardioprotective effects of isoflurane-
induced preconditioning are concentration dependent and
related to the severity of acute hyperglycaemia [9]. More-
over, it has been shown that hyperglycaemia attenuated
cardioprotection via inhibition of Akt and endothelial nitric
oxide synthase (eNOS) phosphorylation [83]. However,
interpretation of abovementioned findings in relation to
T2DM is difficult, because experiments were performed
during acute hyperglycaemia in otherwise healthy animals
without the typical characteristics of T2DM, such as obesity
and insulin resistance.Type 2 diabetes mellitus
T2DM hinders the cardioprotective effects of ischaemic
preconditioning [84], which has been reviewed by Miki
et al. [85]. However, the diabetic rat heart may still
benefit when the preconditioning stimulus is enlarged
[86]. The effects of anaesthesia-induced cardioprotection
in T2DM have however never been studied. In type 1
diabetes, the protective effects of isoflurane-induced
preconditioning were inhibited in case of low isoflurane
concentrations, but not at high concentrations [82].
Further, sevoflurane-induced postconditioning in the
type 1 diabetic heart was disturbed, whereas insulin
treatment to reach normoglycaemia did not restore the
cardioprotective capacity [87]. Mechanisms that are
suggested to be involved include the inhibition of PI3K/Akt
[86,87] and inactivity of mito K+ATP [87]. Furthermore,
AMPK activation during ischaemia protects the non-obese
T2DM Goto-Kakizaki rat heart against reperfusion injury
[88], suggesting a role for AMPK in the cardioprotective
properties of the diabetic heart. A limitation of the
above-described studies is that anaesthesia-induced
cardioprotection is only studied in type 1 diabetes with
insulinopenia and hyperglycaemia, but without char-
acteristics such as obesity, insulin resistance and
hyperinsulinaemia.
Although current findings suggest that the degree of
T2DM, dependent on the presence and severity of
hyperglycaemia and hyperlipidaemia, is of influence for
the cardioprotective capacity of anaesthetics, there
are no direct studies available that investigated
cardioprotective strategies in animals with this diabetic
entity.
Experimental options to improve perioperative
myocardial metabolism
The reduced adaptability of the metabolic altered heart
to ischaemic injury and cardioprotective interventions
warrants further investigation of treatment strategies
that optimise myocardial substrate metabolism before
surgery. It is suggested that volatile anaesthesia induces a
switch from myocardial fatty acid to glucose metabolism.
In the metabolically altered heart, however, myocardial
substrate metabolism is shifted to increased fatty acid and
decreased glucose metabolism. Accordingly, the effect of
volatile anaesthetics seems blunted in the metabolic altered
heart. As a consequence, an improvement of the metabolic
flexibility of the heart may be an important target. Figure 2
shows a hypothetical overview of the effects of different
conditions on myocardial substrate metabolism.
Pharmacological interventions
Improvement of myocardial metabolic flexibility may be
achieved by shifting myocardial substrate metabolism to
glucose metabolism. This can be induced by 1) altering
Fatty acids




















Figure 2 (Hypothetical) Glucose and fatty acid metabolism under different conditions. Glucose and fatty acid metabolism in the healthy
heart (A), during volatile anaesthesia (B), in the metabolic altered heart (C), in the ischaemic heart (D), during volatile anaesthesia in the ischemic
heart (E) and during volatile anaesthesia in the ischemic metabolic altered heart (F). The healthy heart utilises 70% of fatty acids and 30% of
glucose for ATP generation (A). We hypothesise that one of the mechanisms of volatile anaesthesia is the effect on increased glucose
metabolism (B). In the metabolic altered heart it is suggested that myocardial substrate metabolism is shifted to increased fatty acid metabolism
(C), whereas it is suggested that the ischaemic heart is shifted to increased glucose metabolism, however, also contrasting results exist (D). We
hypothesise that exposure of volatile anaesthetics in the ischaemic heart might increase myocardial glucose metabolism even more (E), which is
disturbed in the ischaemic and metabolic altered heart (F).
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3) improving insulin sensitivity. The next paragraphs
provide an overview of pharmacological interventions
in the experimental setting in the treatment of T2DM
and/or myocardial ischaemic injury, which might reduce
perioperative risk due to normalisation of metabolic
derangements (Table 1).
Inhibition of fatty acid metabolism
Carnitine palmitoyl transferase 1 (CPT-1) is a rate-limiting
step of fatty acid oxidation. Several inhibitors of CPT-1
have shown beneficial effects during ischaemia and
reperfusion in rats, such as etomoxir [89-91], perhexiline
[92] and oxfenicine [92,93]. However, not all of these
variants of CPT-1 inhibitors are yet registered for clinical
use. Other possibilities to reduce fatty acid oxidation are
trimetazidine (3-ketoacyl CoA thiolase inhibitor) [94,95],
ranolazine (partial fatty acid oxidation inhibitor) [96,97]
and dichloroacetate (DCA; pyruvate dehydrogenase kinase
inhibitor) [98], which have protective characteristics during
myocardial ischaemia in rats. One of the suggested
mechanisms underlying the beneficial effects of these
substances is the stimulation of myocardial glucoseoxidation [96,98,99]. However, as insulin resistance is a
hallmark of the metabolic altered heart, stimulation of
glucose metabolism via inhibition of fatty acid metabolism
may be blunted during insulin resistance. Unfortunately,
the effect of volatile anaesthesia in combination with
inhibition of fatty acid metabolism on ischaemic injury in
T2DM hearts has not been studied yet, however, based
on the use of these fatty acid inhibitors in models of
T2DM it may be deduced that insulin resistance might
be improved, thereby improving the impact of anaesthesia-
induced cardioprotection.Insulin
Glucose-insulin-potassium (GIK) infusion has been shown
to reduce mortality in non-diabetic [100,101] and diabetic
patients [102], and to reduce infarct size in rats [103].
However, also other results exist [104,105]. In the peri-
operative context, GIK infusion lowered glucose levels and
other metabolic parameters [106] and improved periopera-
tive outcomes, enhanced survival, decreased the incidence
of ischaemic events [107] in T2DM patients during
coronary artery bypass grafting (CABG).
Table 1 Overview of pharmacological interventions in the experimental setting
Drug Applicability Advantages Side-effects
Fatty acid metabolism inhibitors
Etomoxir T2DM, infarction [89-91] Stimulation glucose oxidation [99] -
Perhexiline T2DM, infarction [92] Stimulation glucose oxidation -
Oxfenicine T2DM, infarction [92,93] Stimulation glucose oxidation -
Trimetazidine T2DM, infarction [94,95] Stimulation glucose oxidation -
Ranolazine T2DM, infarction [96,97] Stimulation glucose oxidation [96] -
Dichloroacetate T2DM, infarction [98] Stimulation glucose oxidation [98] -
Insulin
Glucose-insulin-potassium Infarction [103] Stimulation glucose oxidation Hypoglycaemia
Insulin T2DM Reduction glucose levels Hypoglycaemia
Infarction [108,109] Stimulation glucose oxidation Hypoglycaemia
PPAR agonists
Fibrates (PPARα) T2DM [47] Reduction lipids Myopathy
Infarction [115-117] Reduction lipids Myopathy
Thiozolidinediones (PPARγ) T2DM [121,122] Insulin sensitizer Increased risk heart attacks
Infarction [44,48,115,119,120] Insulin sensitizer Increased risk heart attacks
Biguanide
Metformin T2DM, infarction [125-128] Stimulation glucose oxidation Lactic acidosis
GLP1
GLP1 T2DM, infarction [130] Reduction glucose Short half-life
Exendin-4 T2DM, infarction [131] Reduction glucose Hypoglycaemia
Exenatide T2DM, infarction [132] Reduction glucose Hypoglycaemia
Liraglutide T2DM, infarction [133,134] Reduction glucose Hypoglycaemia
T2DM, type 2 diabetes mellitus; PPAR, peroxisome proliferators-activated receptor; GLP-1, glucagon-like peptide 1.
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dial glucose uptake and glycogen content. It is suggested
that insulin itself might be the major cardioprotective
component. In isolated rat hearts, administration of
insulin protected against ischaemia and reperfusion injury
[108,109]. However, insulin treatment was not able to
restore the lost cardioprotective capacity of sevoflurane in
the type 1 diabetic heart [87].
Disadvantages of insulin infusion might be hypoglycaemia,
which could be circumvented by additional glucose infusion
(hyperinsulinaemic euglycaemic clamping). Insulin and
dextrose infusion normalised postoperative whole body
insulin sensitivity and substrate utilization in healthy
patients during elective surgery [110]. During cardiac
surgery, insulin and dextrose infusion maintained normo-
glycaemia in healthy [111] and T2DM [112] patients,
however, hypolipidaemia was observed [113]. Further, it
was shown in diabetic patients that isoflurane reduced
postoperative markers of ischaemic injury after CABG,
indicating a cardioprotective effect of isoflurane [114].
Preoperative treatment with glibenclamide prevented this
protective effect, which was restored by changing
glibenclamide preoperatively to insulin [114]. Takentogether, these data suggest that perioperative glucose
control by insulin may decrease the risk of postoperative
mortality and morbidity.
Peroxisome proliferator-activated receptor agonists
Fibrates are selective peroxisome proliferator-activated
receptor (PPAR)α agonists, which have lipid lowering
effects, thereby improving insulin sensitivity. PPARα
activation has been shown to reduce myocardial ischaemia
and reperfusion injury in rat hearts [115,116]. Activation
of PPARα in T2DM Goto-Kakizaki rat hearts reduced
ischaemic injury [117], whereas in T2DM db/db mice
PPARα activation did not affect the sensitivity to ischaemia
and reperfusion even while myocardial glucose oxidation
was increased and myocardial fatty acid oxidation reduced
[47]. Moreover, sevoflurane reduced PPARα in whole blood
compared to baseline [118], whereas during CABG
sevoflurane reduced PPARα in right atrial tissue compared
to propofol [11]. Based on these contrasting results, it
might be interesting to study the effects of PPARα agonists
combined with volatile anaesthesia.
Insulin-sensitizing drugs, such as thiazolidinediones have
beneficial effects by activation of PPARγ. Rosiglitazone is
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treatment of T2DM. PPARγ agonists have been shown to
reduce myocardial ischaemia and reperfusion injury in rats
[48,115,119,120]. Rosiglitazone has been shown to increase
myocardial GLUT4 translocation [121] and glucose
metabolism [122] in healthy and T2DM rat hearts.
During myocardial ischaemia and reperfusion, it was
shown that rosiglitazone treatment normalised ischaemic
injury by improvement of the reduced glucose uptake in
obese Zucker rats [44], and reduced ischaemic injury by
improved myocardial insulin sensitivity and glucose
oxidation in T2DM Zucker diabetic fatty rats [48],
suggesting a role for PPARγ to influence myocardial
substrate metabolism to optimise metabolic flexibility
during myocardial ischaemia and reperfusion. Accordingly,
it was shown that desflurane-induced cardioprotection
during ischaemia and reperfusion was abolished by PPARγ
inhibition in rabbits [123], suggesting a role for PPARγ in
improvement of metabolic flexibility.
Metformin
Metformin, a biguanide with antihyperglycaemic properties,
has been widely used in the treatment of obesity and
T2DM and exerts its actions by enhancing insulin sensitiv-
ity. It is suggested that the glucose-lowering effects of
metformin are mediated through the activation of AMPK,
which has also been indicated to play an important
protective role in the ischaemic mouse heart [124,125].
In non-diabetic rat hearts, metformin protects against
ischaemic injury [126,127]. Accordingly, metformin
provides cardioprotection against ischaemic injury in
T2DM hearts from animals in vivo [125], but not in vitro
[128]. The effects of volatile anaesthesia and metformin in
ischaemic and T2DM hearts has not been studied yet.
However, it has been shown that AMPK is involved in
anaesthetic cardioprotection [41,129].
Glucagon-like peptide 1
Glucagon-like peptide 1 (GLP1) is a gut incretin hor-
mone that is released in response to nutrient intake,
stimulates insulin secretion and exerts insulinotropic
and insulinomimetic properties. GLP1 has been shown
to be protective in ischaemic rat hearts [130].
GLP1 has a short half-life of several minutes, due to
rapid breakdown by dipeptidyl peptidase IV (DPP4).
Exendin-4 is a peptide derived from the saliva of the gila
monster which mimics GLP1, but is resistant to degrad-
ation by DPP4. Exenatide and liraglutide are synthetic
GLP1 analogues, which mimic human GLP1 and are
currently used for blood glucose-lowering therapy in
T2DM. Exendin-4 [131], exenatide [132] and liraglutide
[133] have been shown to reduce infarct size in animals,
but also a neutral effect of liraglutide on myocardial
infarct size was found [134]. Another possibility tocircumvent the rapid breakdown of GLP1 is the use of a
DPP4 inhibitor. However, inhibition of DPP4 by valine
pyrrolidide in rats [130] or in DPP4 knockout mice
[135] was not protective during myocardial infarction. It
is suggested that the cardioprotective effect is a conse-
quence of insulin, however, GLP1 has cardioprotective
effects both in vivo and in vitro, whereby the latter is in
absence of circulating insulin levels [130], suggesting a
role for GLP1 in cardioprotection.
The mechanism behind the cardioprotective properties
of GLP1 may, amongst others [136], rely on improving
myocardial glucose metabolism. GLP1 increased glucose
uptake in isolated mouse [137] and isolated healthy [138],
hypertensive [139] and ischaemic/reperfused [138] rat
hearts. Moreover, exenatide increased myocardial glucose
uptake in healthy [140] and insulin resistant dilated cardio-
myopathy [141] mice, whereas it did not alter myocardial
glucose uptake in type 2 diabetic patients [142].
Exposure of healthy rats to isoflurane anaesthesia
decreased GLP1 levels, without affecting DPP4 activity,
insulin and glucose levels [143], suggesting impaired
GLP1 secretion during isoflurane anaesthesia. However,
the effect of volatile anaesthetics on GLP1 is scarcely
studied and therefore no conclusion van be drawn.
Taken together, the above-discussed pharmacological
interventions suggest that improving insulin sensitivity,
and thereby improving myocardial flexibility, may be the
most beneficial option in metabolically altered hearts in
order to restore cardioprotective mechanisms. However,
according to current clinical practice, oral hypoglycaemic
agents are usually withheld before surgery in order to
avoid associated adverse effects, such as perioperative
hypoglycaemia or lactic acidosis. Therefore the (clinical)
feasibility and safety of the proposed interventions should
be carefully studied and weighted against the potential risk
of these adverse effects.
Preoperative health risk improvement
Based on 7 risk factors (physical inactivity, dietary pattern,
obesity, smoking, high cholesterol, hypertension and
elevated blood glucose levels), the 2020 impact goal of the
American Heart Association is: “to improve the cardiovas-
cular health by 20% while reducing deaths from cardiovas-
cular diseases and stroke by 20%” [144]. Another possibility
besides pharmacological intervention is preoperative
lifestyle intervention, such as changing the dietary intake
and stimulation of physical activity thereby losing weight
and improving insulin sensitivity.
It has been shown by reducing dietary fat in rodents
that diet-induced obesity is reversible [145-147]. In con-
trast, diet-induced obesity was not reversed by withdrawal
of an energy dense diet [148]. Reversibility of diet-induced
obesity is independent of the duration of the obese state
[146], whereas long-term diet feeding did not reversed
van den Brom et al. Cardiovascular Diabetology 2013, 12:42 Page 9 of 13
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ary intake may have beneficial effects on health. However,
there is only limited literature available that describes the
effects of changing dietary balance on the heart.
In western diet-fed rats, lowering caloric intake
improved systolic and diastolic function and prevented
sevoflurane-induced cardiodepression (van den Brom et al.,
unpublished observations). Accordingly, pacing-induced
cardioprotection was lost by diet-induced hypercholesterol-
aemia, but restored after reversion to control diet [149],
whereas caloric restriction by itself in healthy rats also has
cardioprotective properties [150]. In conclusion, restriction
of dietary fat seems an effective treatment to improve
metabolic flexibility of the heart and thereby may be a
possibility to reduce perioperative risk.
Obesity and T2DM are closely related to physical
inactivity, and exercise could be a possible lifestyle
intervention to reduce perioperative risk. The benefits of
exercise with respect to obesity and T2DM are already
recognized clinically [151]. However, the effects of
exercise on myocardial infarction are contradictory.
Exercise did not reduce myocardial ischaemic injury in
rats [152], whereas others showed that exercise had
protective effects in rat hearts [153-155]. The question
remains if exercise has beneficial effects in obese and
T2DM on myocardial function and ischaemia and reperfu-
sion injury. Exercise was shown to reverse diet-induced
obesity, insulin resistance and cardiomyocyte dysfunction
[147], however, the effects of exercise on myocardial
infarction in obese and T2DM with and without the effects
of volatile anaesthesia is not known. Based on the above
described results exercise might be a possible lifestyle
intervention to reduce perioperative risk.Conclusions
Over the years, several mechanisms that are involved in
anaesthesia-induced cardioprotection have been evaluated
in the experimental setting. The existing evidence suggests
that the obese and/or T2DM heart is less adaptable to
cardioprotective interventions and that anaesthesia-induced
cardioprotection is just a “healthy heart phenomenon”.
Differences between experimental models, the type
of metabolic disease and the severity of myocardial
substrate derangements challenge the identification of
unifying mechanisms related to anaesthesia-induced
cardioprotection in cases of obesity and T2DM. It
might be deduced that interventional options should
focus on recovery of the metabolic flexibility of the heart,
especially by improving insulin sensitivity. Although chan-
ging lifestyle seems promising to reduce the susceptibility
of the heart to intraoperative ischaemia and reperfusion
injury, experimental data has not been translated into
clinical data. Therefore more studies are required toelucidate whether these interventions have beneficial
effects on perioperative outcome.
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